The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

While billions pour into pharmaceutical biotech, officials and experts warn there’s much less private investment in products more relevant to the military, like body armor materials, anti-corrosion ...

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

Protein synthesis is vital for life, translating genetic information from DNA to functional proteins through transcription ...

In an exclusive interview, one of UCLA's top scientists spoke out about what the disruptions in funding could mean to you and to science.

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

Preventing the cell's protein factories from making the notorious cancer-causing protein MYC could stop out-of-control tumors.

A team from UNIGE, the Max Planck Institute for Molecular Physiology in Dortmund, and Heinrich Heine University in Düsseldorf ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

UCSF scientists discover how cancer cells hijack the protein factory of the cell to churn out MYC protein, the driver of 70% ...